TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11600827
Drug: Triple-therapy protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-therapy protocol (zidovudine/lamivudine or stavudine/didanosine or stavudine/lamivudine with protease inhibitor)
Study: 11600827
Drug: Treatment intensification
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment intensification protocol (ritonavir/saquinavir or ritonavir/saquinavir/stavudine)
Study: 11600827
Drug: Discontinued study
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinued study medication
Study: 3289770
Drug: Succinylcholine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 1.5 mg.kg‐1 after pre‐treatment with d‐tubocurarine 0.05 mg.kg‐1
Study: 3289770
Drug: Atracurium 350
Normalized name: Atracurium
DrugBank: Atracurium (DB13295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atracurium 350 micrograms.kg‐1 after a priming dose of 50 micrograms.kg‐1
Study: 31867653
Drug: Cigarettes with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarettes with <15.8 mg/g nicotine
Study: 31867653
Drug: Higher nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher nicotine doses (2.4, 5.2, and 15.8 mg/g of tobacco)
Study: 26116711
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1,800 mg/day for 4 days plus 2,700 mg before the experimental session
Study: 9049659
Drug: AM3 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AM3 treatment
Study: 3011891
Drug: Lacto-ovo-vegetarian (L-O-V)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacto-ovo-vegetarian (L-O-V) diet
Study: 28746788
Drug: Dexamethasone regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone regimen (day 1: intravenous dexamethasone [20 mg] and granisetron [3 mg] before TACE; days 2 and 3: intravenous dexamethasone [8 mg])
Study: 28746788
Drug: Control regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control regimen (day 1: intravenous placebo [saline] and granisetron [3 mg]; days 2 and 3: intravenous placebo)
Study: 16671258
Drug: Succinylcholine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine (1 mg x Kg(-1)) followed by Mivacurium (100 microg x Kg(-1))
Study: 16671258
Drug: Succinylcholine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine (1 mg x Kg(-1)) preceded by Mivacurium (10 microg x Kg(-1)) and followed by Mivacurium (100 microg x Kg(-1))
Study: 12858075
Drug: Adjunctive therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive therapies (corticosteroids, antiplatelet drugs, immunosuppressive agents)
Study: 9183482
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solutions (ORS)
Study: 2419292
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (CTX) followed by standard treatment (STD RX)
Study: 2419292
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (STD RX; preoperative irradiation and radical excision or irradiation alone)
Study: 2419292
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (STD RX)
Study: 25421518
Drug: Treatment dropouts
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment dropouts (n=185)
Study: 20127419
Drug: ICD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD treatment with ACE medication
Study: 20127419
Drug: ICD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD treatment without ACE medication
Study: 15790985
Drug: Salmeterol/fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone propionate combination 50/500 microg twice daily
Study: 9763554
Drug: ATRA followed
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATRA followed by chemotherapy (CT)
Study: 7828253
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine with saline PCEA (Group 2)
Study: 7828253
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine without saline PCEA (Group 3)
Study: 2969638
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day of HPR
Study: 2969638
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day of HPR
Study: 2969638
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day of HPR
Study: 1385959
Drug: Niceritrol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niceritrol 1.5 g daily for 12 weeks (b.i.d.)
Study: 1385959
Drug: Niceritrol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niceritrol 1.5 g daily for 12 weeks (t.i.d.)
Study: 1385959
Drug: Niceritrol in
Normalized name: niceritrol
DrugBank: Niceritrol (DB13441)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niceritrol in patients with initially high Lp(a) (≥20 mg/dl)
Study: 356507
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (1.05 mg/kg body weight)
Study: 28349233
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol (CBD) 10 mg orally twice daily for 8 weeks
Study: 23642329
Drug: Aflibercept (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept (4 mg/kg every 2 weeks) combined with gemcitabine (1000 mg/m² i.v. weekly for 7 weeks out of 8, then weekly for 3 weeks out of 4)
Study: 23642329
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m² i.v. weekly for 7 weeks out of 8, then weekly for 3 weeks out of 4) plus placebo
Study: 23642329
Drug: Aflibercept (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept (4 mg/kg every 2 weeks) combined with gemcitabine
Study: 23642329
Drug: Aflibercept (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept (4 mg/kg every 2 weeks)
Study: 15204513
Drug: Qigong (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qigong (treatment group)
Study: 11182866
Drug: 12-Step focused
Normalized name: STEP 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-Step focused group treatment
Study: 8162480
Drug: Spa therapy
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa therapy for chronic low back pain (3-week therapy programme)
Study: 8162480
Drug: Spa therapy
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa therapy for chronic low back pain (9 months follow-up)
Study: 3227043
Drug: Naloxone 210
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 210 mg
Study: 3227043
Drug: Morphine 15-30
Normalized name: morphine 15 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 15-30 mg
Study: 26791800
Drug: Triple antiemetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiemetic therapy with aprepitant, palonosetron, and dexamethasone
Study: 26791800
Drug: Double antiemetic
Normalized name: ANTIEMETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double antiemetic therapy with palonosetron and dexamethasone
Study: 23816610
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus extended-release dipyridamole (ASA + ERDP)
Study: 20581703
Drug: Weekly undulating
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly undulating (WUD) strength training
Study: 18084048
Drug: No r‐hLH
Approvals — FDA: no, EMA: no, PMDA: no
Description: No r‐hLH treatment
Study: 7868662
Drug: ICI 182,780,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 182,780, 12 mg daily for 7 days
Study: 7868662
Drug: ICI 182,780
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 182,780 treatment group
Study: 3044182
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg diltiazem before induction of anesthesia
Study: 3044182
Drug: 0.014 mg
Normalized name: phenol 0.014 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.014 mg diltiazem/kg per min over 20 min before cannulation
Study: 3044182
Drug: 0.014 mg
Normalized name: phenol 0.014 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.014 mg diltiazem/kg per min during ECC
Study: 21330912
Drug: Extended-dose nevirapine
Normalized name: nevirapine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-dose nevirapine
Study: 21330912
Drug: Extended-dose nevirapine
Normalized name: nevirapine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-dose nevirapine (for mothers with CD4 > 350 cells/μl)
Study: 19826272
Drug: Propranolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (1 mg/kg/d, max 1.98 mg/kg/d in six divided doses)
Study: 16400058
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg I (as oral iodized oil)
Study: 11417301
Drug: Anti-endothelial cell
Normalized name: AECA - Anti-endothelial cell antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-endothelial cell antibody (AECA) titer measurement in renal transplant recipients with acute rejection (n = 27)
Study: 11417301
Drug: Anti-endothelial cell
Normalized name: AECA - Anti-endothelial cell antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-endothelial cell antibody (AECA) titer measurement post-rejection therapy
Study: 1288238
Drug: UFT (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (400 mg per day for 6 months)
Study: 3834100
Drug: Program model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Program model considering clinical decision making based on patient characteristics, intensity of care, and treatment modalities
Study: 27919589
Drug: M +
Normalized name: Calcium + D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: M + R (1% lidocaine 8 mL + morphine 2 mg + ropivacaine 20 mg)
Study: 27919589
Drug: M +
Normalized name: Calcium + D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: M + R + K (1% lidocaine 8 mL + morphine 2 mg + ropivacaine 20 mg + ketamine 20 mg)
Study: 27919589
Drug: M +
Normalized name: Calcium + D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: M + R + N (1% lidocaine 8 mL + morphine 2 mg + ropivacaine 20 mg + naloxone 2 μg)
Study: 27919589
Drug: M +
Normalized name: Calcium + D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: M + R + K + N (1% lidocaine 8 mL + morphine 2 mg + ropivacaine 20 mg + ketamine 20 mg + naloxone 2 μg)
Study: 24930639
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + MTZ (400 mg TID) + AMX (500 mg TID) for 14 days
Study: 20958856
Drug: 980 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 980 nm InGasAs diode laser (power 15 W, spot size 8 mm, time 3 seconds, fluence 90 J/cm(2)) applied weekly for 9 weeks
Study: 17910603
Drug: sustained-release melatonin
Normalized name: melatonin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: sustained-release melatonin
Study: 16086149
Drug: Chronic opioid
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic opioid therapy with antidepressant
Study: 12135028
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg p.o. every 12 h)
Study: 12135028
Drug: Endoscopic ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endoscopic ethanol injection therapy
Study: 10396712
Drug: Thiamylal 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamylal 4 mg/kg
Study: 10468248
Drug: A4 (28,572
Approvals — FDA: no, EMA: no, PMDA: no
Description: A4 (28,572 KIU/kg of aprotinin before surgery, followed by continuous infusion of 7,143 KIU/kg/h until the end of surgery)
Study: 10468248
Drug: A2 (14,286
Approvals — FDA: no, EMA: no, PMDA: no
Description: A2 (14,286 KIU/kg of aprotinin before surgery, followed by continuous infusion of 7,143 KIU/kg/h until the end of surgery)
Study: 1859488
Drug: Oral azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azathioprine plus cyclophosphamide
Study: 6303373
Drug: Metoprolol 200
Normalized name: metoprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 200 mg in a slow‐release tablet once daily for 4 days and 10 mg i.v. shortly before induction of anaesthesia
Study: 6303373
Drug: Fentanyl 1.0‐1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1.0‐1.5 mg during anaesthesia
Study: 6303373
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets and physiological saline i.v.
Study: 31468618
Drug: Half-dose bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Half-dose bevacizumab therapy (7.5 mg/kg every 3-4 weeks)
Study: 29496069
Drug: Cetuximab or
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab or Bevacizumab in combination with fluorouracil, folinic acid, and irinotecan (first-line therapy)
Study: 12431965
Drug: Marimastat 10
Normalized name: Marimastat
DrugBank: Marimastat (DB00786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marimastat 10 mg orally bid for up to 2 years
Study: 8950069
Drug: Guided antiarrhythmic
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided antiarrhythmic therapy (class I, II, and III antiarrhythmic drugs)
Study: 1758710
Drug: Continuous Infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Infusion (CI)
Study: 6759059
Drug: timolol/hydrochlorothiazide/amiloride preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: timolol/hydrochlorothiazide/amiloride preparation
Study: 26031762
Drug: Nebulized fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nebulized fentanyl (250 μg)
Study: 24214779
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg morphine sulfate
Study: 24214779
Drug: 0.10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.10 mg/kg morphine sulfate
Study: 21745374
Drug: Plasma exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma exchange (PE) one volume daily for 5 days
Study: 19966527
Drug: Lornoxicam (LOR)
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam (LOR) 8 mg
Study: 19966527
Drug: Lornoxicam (LOR)
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam (LOR) 16 mg
Study: 17445841
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (early surgery)
Study: 9824265
Drug: Terlipressin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (2 mg/day for 2 days)
Study: 6446778
Drug: Intravenous spectinomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous spectinomycin hydrochloride (8 g per day)
Study: 6446778
Drug: Aqueous penicillin
Normalized name: penicillin G procaine Injectable Suspension [Pen-Aqueous]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous penicillin G (2.0 x 10(7) units per day, iv) plus kanamycin (1 g per day, im)
Study: 23379537
Drug: OC000459 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC000459 (100 mg, twice daily)
Study: 21110526
Drug: Adalimumab 80
Normalized name: ADALIMUMAB 80MG/0.8ML INJ PEN KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 80 mg at baseline followed by 40 mg every other week from week 1 to week 15
Study: 19466961
Drug: High-dose UVB
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose UVB therapy (40% incremental doses, three times weekly)
Study: 19466961
Drug: Low-dose UVB
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose UVB therapy (20% incremental doses, three times weekly)
Study: 11495180
Drug: Fluoxetine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (30 or 60 mg) with behavioral counseling
Study: 9721156
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg igmesine
Study: 9721156
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg igmesine
Study: 8036824
Drug: Intradermal purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal purified chick embryo cell rabies vaccine (PCEC) alone (0.1 ml at each of two sites on days 0, 3, and 7, and at one site on days 28 and 90) (n = 81)
Study: 8036824
Drug: Intradermal PCEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal PCEC with one dose of human rabies immunoglobulin (HRIG) intramuscularly at 20 IU kg‐1 on day 0 (n = 52)
Study: 27959715
Drug: Inclisiran (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inclisiran (300 mg or more, single dose)
Study: 27959715
Drug: Inclisiran (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inclisiran (100 mg or more, single dose)
Study: 27959715
Drug: Inclisiran (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inclisiran (multiple doses)
Study: 26189484
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate 0.05% ointment (corticosteroid group)
Study: 24204065
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (weekly for up to 14 weeks)
Study: 19414946
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg/day for 6 months
Study: 19414946
Drug: Vitamin B-12
Normalized name: Vitamin B-12
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B-12 500 mcg/day
Study: 8329880
Drug: Conjoint therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjoint therapy component in social-learning-based alcoholism treatment
Study: 8329880
Drug: Social-learning-based alcoholism
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social-learning-based alcoholism treatment without conjoint therapy
Study: 8329880
Drug: Conjoint treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjoint treatment with high-autonomy alcoholics
Study: 8329880
Drug: Treatment without
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment without other family members for low-autonomy alcoholics
Study: 3525077
Drug: Busulfan (4-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Busulfan (4-6 mg/day during 4-8 weeks, with re-administration at relapse)
Study: 22456602
Drug: Six times
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six times per week hemodialysis (Daily Trial)
Study: 22456602
Drug: Three times
Normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times per week hemodialysis (Daily Trial)
Study: 15826611
Drug: Clarified appearance
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarified appearance question (e.g., 'What does the sponge look like?')
Study: 8875683
Drug: Furosemide (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (15 mg/kg)
Study: 6203596
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dextran 70 and dihydroergotamine (DHE)
Study: 31579904
Drug: empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: empagliflozin 10 or 25 mg
Study: 24646104
Drug: Denosumab 60
Normalized name: denosumab 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 60 mg sc every 6 months (n = 500)
Study: 24646104
Drug: Oral alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alendronate 35 mg weekly (n = 251)
Study: 20222915
Drug: lesogaberan (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: lesogaberan (0.8 mg/kg)
Study: 20222915
Drug: baclofen (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: baclofen (40 mg)
Study: 18019850
Drug: d‐threo‐methylphenidate (d‐MPH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐threo‐methylphenidate (d‐MPH) 5‐15 mg twice daily
Study: 9505155
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g SPP
Study: 9505155
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g SPP (raw)
Study: 9505155
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g SPP (baked into bread)
Study: 9505155
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g oat bran
Study: 9505155
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g wheat bran
Study: 9505155
Drug: 180 g
Normalized name: GLYCERIN 9 mg in 180 g / PANTHENOL 7 mg in 180 g CUTANEOUS FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 g wheat flour (control bread)
Study: 9505155
Drug: 180 g
Normalized name: GLYCERIN 9 mg in 180 g / PANTHENOL 7 mg in 180 g CUTANEOUS FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 g wheat flour with 20 g raw SPP (bread)
Study: 9505155
Drug: 180 g
Normalized name: GLYCERIN 9 mg in 180 g / PANTHENOL 7 mg in 180 g CUTANEOUS FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 g wheat flour with 20 g SPP (baked bread)
Study: 2507265
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin plus 10 mg glyburide
Study: 799563
Drug: Timolol alone
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol alone (10 mg)